drugset / Trial / NCT04395170

Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

NCT04395170

Phase 2/3 Unknown 75 enrolled Lifefactors Zona Franca, SAS
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

Timeline

Start
2020-09
Primary completion
2020-12
Completion
2021-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-COVID-19 human immunoglobulin Protein / enzyme biologic 1 unknown Intravenous
Subject Anti-COVID-19 human immunoglobulin Protein / enzyme biologic 50 ml Intravenous
Subject Convalescent Plasma Protein / enzyme biologic 200 ml
Subject Convalescent Plasma Protein / enzyme biologic 250 ml
Background Azithromycin Small molecule
Background Chloroquine Small molecule
Background Hydroxychloroquine Small molecule
Background Remdesivir Small molecule

Indications